News | November 02, 2025
Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Investment to expand manufacturing and global medicine supply capacity
Subscribe To Our Newsletter & Stay Updated
